Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dorzagliatin Effects on Insulin Secretion in Intermediate Hyperglycemia and Type 2 Diabetes
NCT06671340Not yet recruiting
- Start
- Apr 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of dorzagliatin in type 2 diabetes mellitus (T2DM) and prediabetes. Primary endpoint: Acute Insulin Secretion at 4 weeks. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
dorzagliatin
03
Conditions
type 2 diabetes mellitus (T2DM)prediabetes
Beyond the preview
Go deeper on NCT06671340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06671340.